Physician profile
Caley Bogatz
NPI 1699377515
$2,520.68
in general payments reported to CMS, 2019-2025
31 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $350 · 2023: $460 · 2024: $432 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $910.97 | 2021-2025 | |
| Pfizer INC. | $219.67 | 2023-2025 | |
| Novo Nordisk INC | $211.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.45 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $107.46 | 2022-2025 | Xigduo, Bydureon |
| Janssen Pharmaceuticals, INC | $99.39 | 2022-2025 | Spravato, Invega Sustenna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.69 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $73.30 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.56 | 2023-2024 | Xifaxan |
| Amgen INC. | $70.39 | 2021-2024 | Evenity, Prolia, Repatha |
| Sanofi-Aventis U.S. LLC | $57.09 | 2023-2025 | |
| Lilly USA, LLC | $46.23 | 2024-2025 | Mounjaro, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $43.61 | 2022 | |
| Boston Scientific Corporation | $40.50 | 2024-2025 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $34.38 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $33.37 | 2024 | Impella |
| Lundbeck LLC | $32.35 | 2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $32.21 | 2024-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $30.47 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $29.13 | 2022-2023 | Vaxneuvance, Gardasil 9, Proquad |
| Axsome Therapeutics, INC. | $26.57 | 2022-2025 | Symbravo |
| Kowa Pharmaceuticals America, INC. | $26.46 | 2022-2025 | Zoryve |
| Vanda Pharmaceuticals INC. | $21.65 | 2024 | Fanapt, Hetlioz |
| Phathom Pharmaceuticals, INC. | $17.63 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $17.50 | 2021 | |
| Inspire Medical Systems, INC. | $17.14 | 2025 | Inspire |
| Medtronic, INC. | $14.19 | 2024 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $13.92 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $12.89 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caley Bogatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.